Coronavirus (COVID-19): visiting The Royal Marsden suspended

Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Please see more information here about how we are keeping everyone safe.

Haemato-oncology clinical trials

Clinical trials are an important part of improving treatment for patients.

Acute leukaemias

Acute myeloid leukaemia (AML) trials

  • IDH1 inhibitor study for adults with AML with IDH1 mutation, either relapsed or refractory to conventional treatment or for those unsuitable for conventional treatment at presentation.
  • Trial of MDM2 antagonist in combination with low intensity chemotherapy for relapsed/refractory AML with wild type TP53 in adults
  • AML19 for untreated patients aged 18-60 years with AML. Looking at the combination of gemtuzumab ozogamicin and midostaurin in combination with standard chemotherapy
  • AML18 for untreated patients aged over 60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy

Acute lymphoblastic leukaemia (ALL) trials

  • UKALL2011 trial for young adults aged 18-24 years with untreated ALL, looking at different doses of steroids and high dose methotrexate
  • MEK inhibitor trial for relapsed/refractory acute lymphoblastic leukaemia with RAS-pathway mutations in adults.
  • Daratumumab plus chemotherapy for first relapsed/refractory T acute lymphoblastic leukaemia in young adults (<30 years)

Chronic lymphoid leukaemias

  • Randomised clinical trial comparing R-FC to R-Ibrutinib in treatment naïve CLL patients with intact TP53
  • Randomised clinical trial comparing Ibrutinib to Acalabrutinib in patients with previously treated CLL with ATM or TP53 loss

Lymphoma

  • A dose-finding study of single agent idelalisib in the treatment of double-refractory follicular lymphoma
  • A clinical trial of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory DL

Myelodysplastic syndromes and other myeloid disorders

For patients with low blood counts of uncertain cause we have a gene sequencing study to test whether any genes are mutated.

 

Academic and commercial trials are run through the Haemato-oncology Unit. Trials that are currently recruiting are listed below under each disease category.

Please email us for more information about our haemato-oncology clinical trials.